retatrutide clinical trials news A new trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss and diabetes Some People Lost Too Much

Of note, individuals with emotional eating are less sensitive to the central effects of GLP-1 RA brain activations [61, 62] but no clinical proof of poorer weight loss has been found so far [63]

Nutrients 13(12):4212 Begh MZA, Khan J, Zehravi M, Sweilam SH, Raja AD, Muthukumar A, Haque MA, Kar NR, Singh LP, Priya BD, Alshehri MA, Ahmad I, Kang S, Moon S, Park MN, Emran TB, Kim B (2024) Targeting neurological disorders with stilbenes: bridging the preclinical-clinical gap

Gastrointestinal complications (gastroparesis): GLP-1 medications slow digestion by delaying stomach emptying

However, these insights can help frame conversations with your provider about whether additional monitoring or proactive management strategies may be beneficial for you